Record citatie

APA (7e ed.) Bronvermelding
Kim, J. S., Song, Y., Jen, W., Chim, C. S., Lee, J., Yoon, S., . . . Chng, W. (2025). Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: An Asian Myeloma Network study (AMN003). Nature Publishing Group.
Chicago (17e ed.) Bronvermelding
Kim, Jin Seok, et al. Randomized Phase 3 Study of Pomalidomide Cyclophosphamide Dexamethasone Versus Pomalidomide Dexamethasone in Relapse or Refractory Myeloma: An Asian Myeloma Network Study (AMN003). Nature Publishing Group, 2025.
MLA (9e ed.) Bronvermelding
Kim, Jin Seok, et al. Randomized Phase 3 Study of Pomalidomide Cyclophosphamide Dexamethasone Versus Pomalidomide Dexamethasone in Relapse or Refractory Myeloma: An Asian Myeloma Network Study (AMN003). Nature Publishing Group, 2025.
Let op: Deze citaties zijn niet altijd 100% accuraat.